Absorica Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Let's reconsider modern progestin-only pills during isotretinoin and retinoid therapy
Eur J Contracept Reprod Health Care. 2024 Mar 1:1-3. doi: 10.1080/13625187.2024.2315239. Online ahead of print.NO ABSTRACTPMID:38426353 | DOI:10.1080/13625187.2024.2315239 (Source: The European Journal of Contraception and Reproductive Health Care)
Source: The European Journal of Contraception and Reproductive Health Care - March 1, 2024 Category: Reproduction Medicine Authors: Marco Manfredini Lucio Di Castri Giovanni Grandi Source Type: research

Practices, Efficacy, and Reported Side Effects Associated with Isotretinoin Treatment in Palestine
(Source: Patient Preference and Adherence)
Source: Patient Preference and Adherence - February 23, 2024 Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research

Balancing Ethical Principles in Dermatology: Disclosing Clinical Trial Underrepresentation During Informed Consent
I was recently approached by a medical student on an elective who asked me if speaking about the lack of clinical trial representation for patients from minoritized groups during informed consent is ethically appropriate or necessary. The specific scenario was a transgender man starting isotretinoin therapy. (Source: Clinics in Dermatology)
Source: Clinics in Dermatology - February 22, 2024 Category: Dermatology Authors: Alana Ferreira, Jeromy W. Gotschall, Jane M. Grant-Kels Source Type: research

How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians
Clin Pharmacol Ther. 2024 Feb 20. doi: 10.1002/cpt.3189. Online ahead of print.ABSTRACTThe US Food and Drug Administration can require risk evaluation and mitigation strategy (REMS) programs for prescription drugs to ensure the benefits of use outweigh the risks. We conducted a national survey of physicians' experiences prescribing eight REMS-covered drugs: (1) ambrisentan; (2) bosentan; (3) clozapine; (4) isotretinoin; (5-7) the multiple myeloma (MM) drugs lenalidomide, pomalidomide, thalidomide; and (8) sodium oxybate. Between May 2022 and January 2023, we surveyed 5,331 physician prescribers of these drugs, and 1,295 (2...
Source: Clinical Pharmacology and Therapeutics - February 20, 2024 Category: Drugs & Pharmacology Authors: Ameet Sarpatwari Zhigang Lu Massimiliano Russo Heidi Zakoul Su Been Lee Gita A Toyserkani Esther H Zhou Cynthia LaCivita Katherine Hyatt Hawkins Shaw Laura Zendel Gerald J Dal Pan Aaron S Kesselheim Source Type: research

Increasing awareness of the risk of drug-induced intracranial hypertension in patients with acne requiring treatment for bacterial STI
Drug-induced intracranial hypertension (DIIH) is a condition characterised by headaches, impaired visual acuity, visual field defects and blindness as a result of papilloedema,1 where a temporal link between symptoms and medication onset can be clearly defined. Although there are limited data describing the natural course of DIIH, discontinuation of the inciting drug is only sufficient in some cases.1 DIIH as a result of co-prescription with tetracycline-class antibiotics, and isotretinoin has been well documented in the literature.1 Isotretinoin is prescribed for severe, recalcitrant acne vulgaris, which is most prevalent...
Source: Sexually Transmitted Infections - February 19, 2024 Category: Sexual Medicine Authors: Louly Nathan, A., OBroin, C., Lally, A. Tags: PostScript Source Type: research

Perceptions, Utilization, and Cost Assessment of Sebaceous Hyperplasia Treatment Modalities: A Pilot Survey
CONCLUSION: SH is a common issue that presents in the dermatologist's office. These data highlight the perception that ED is the most common approach employed, associated with lower costs, and requiring fewer sessions to achieve resolution. More data is needed and wanted to better determine best practices for the management of SH.J Drugs Dermatol. 2024;23(2):29-37.  doi:10.36849/JDD.7734.PMID:38306143 | DOI:10.36849/JDD.7734 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - February 2, 2024 Category: Dermatology Authors: S H Millan G E Sellyn Adam J Friedman Source Type: research